{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:26:32Z","timestamp":1785425192047,"version":"3.56.0"},"reference-count":16,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Human papillomavirus (HPV) is widely recognised for its role in causing cervical cancer, prompting many countries, including South Africa, to prioritise girls in school-based vaccination programmes. This short report presents an exploratory case for expanding HPV vaccination to adolescent boys as well, drawing on emerging, but still limited evidence of maternal and paternal HPV transmission to neonates. Although current data on neonatal risks are preliminary, the possibility of vertical transmission and associations with respiratory papillomatosis, preterm birth and fertility issues warrant further investigation. Beyond neonatal outcomes, gender-neutral HPV vaccination offers ethical and public health benefits by promoting equitable protection, enhancing herd immunity and addressing transmission dynamics. Recent advances, including the World Health Organization-endorsed single-dose schedules and the availability of affordable vaccines, provide opportunities to revisit cost-effectiveness analyses. We recommend further context-specific research and modelling to quantify the long-term benefits of gender-neutral strategies in South Africa and similar settings.<\/jats:p>","DOI":"10.4102\/phcfm.v17i1.5035","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:44:02Z","timestamp":1759153442000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Expanding the case for gender-neutral human papillomavirus vaccination in South Africa: Emerging neonatal and ethical considerations"],"prefix":"10.4102","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2558-6226","authenticated-orcid":false,"given":"Vanessa C.","family":"Scheepers","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0549-9117","authenticated-orcid":false,"suffix":"Gardner","family":"Jillian","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rp50x72","id-type":"ROR","asserted-by":"publisher"}],"name":"University of the Witwatersrand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"ref0","unstructured":"National Department of Health, South Africa. Cervical cancer prevention and control policy [homepage on the Internet]. Pretoria: NDoH; 2017 [cited 2024 Jul 14]. Available from: https:\/\/www.health.gov.za\/wp-content\/uploads\/2021\/07\/cervical-cancer-policy.pdf"},{"key":"ref1","unstructured":"World Health Organization. Human papillomavirus vaccines: WHO position paper (2022 update) [homepage on the Internet]. Wkly Epidemiol Rec. 2022 [cited 2025 May 06];97(50):645\u2013672. Available from: https:\/\/www.who.int\/publications\/i\/item\/who-wer9750-645-672"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Ardekani A, Taherifard E, Mollalo A, et al. Human papillomavirus infection during pregnancy and childhood: A comprehensive review. Microorganisms. 2022;10(10): 1932. https:\/\/doi.org\/10.3390\/microorganisms10101932","DOI":"10.3390\/microorganisms10101932"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs D, Szab\u00f3 A, Hegyi P, et al. Association between human papillomavirus and preterm delivery: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2024;103(10):1933\u20131942. https:\/\/doi.org\/10.1111\/aogs.14913","DOI":"10.1111\/aogs.14913"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Niyibizi J, Mayrand MH, Audibert F, et al. Association between human papillomavirus infection among pregnant women and preterm birth. JAMA Netw Open. 2021;4(9):e2125308. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.25308","DOI":"10.1001\/jamanetworkopen.2021.25308"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Skoczy\u0144ski M, Go\u017adzicka-J\u00f3zefiak A, Kwa\u015bniewska A. Co-occurrence of human papillomavirus (HPV) in newborns and their parents. BMC Infect Dis. 2019;19:930. https:\/\/doi.org\/10.1186\/s12879-019-4503-4","DOI":"10.1186\/s12879-019-4503-4"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Busnelli A, Garolla A, Tersigni C, et al. Sperm human papillomavirus infection and risk of idiopathic recurrent pregnancy loss: Insights from a multicenter case-control study. Fertil Steril. 2023;119(3):410418. https:\/\/doi.org\/10.1016\/j.fertnstert.2022.12.002","DOI":"10.1016\/j.fertnstert.2022.12.002"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gray P, Kann H, Pimenoff VN, et al. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. PLoS Med. 2021;18(6):e1003588. https:\/\/doi.org\/10.1371\/journal.pmed.1003588","DOI":"10.1371\/journal.pmed.1003588"},{"key":"ref8","unstructured":"Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases [homepage on the Internet]. 14th ed. Washington, DC: Public Health Foundation; 2021 [cited 2025 May 06], Chapter 11: Human papillomavirus. Available from: https:\/\/www.cdc.gov\/pinkbook\/hcp\/table-of-contents\/chapter-11-human-papillomavirus.html"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Lehtinen M, Gray P, Louvanto K, V\u00e4nsk\u00e4 S. In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers. Expert Rev Vaccines. 2022;21(6):735\u2013738. https:\/\/doi.org\/10.1080\/14760584.2022.2064279","DOI":"10.1080\/14760584.2022.2064279"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Sundaram N, Voo TC, Tam CC. Adolescent HPV vaccination: Empowerment, equity and ethics. Hum Vaccin Immunother. 2020;16(8):1835\u20131840. https:\/\/doi.org\/10.1080\/21645515.2019.1697596","DOI":"10.1080\/21645515.2019.1697596"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Luyten J, Engelen B, Beutels P. The sexual ethics of HPV vaccination for boys. HEC Forum. 2014;26(1):27\u201342. https:\/\/doi.org\/10.1007\/s10730-013-9219-z","DOI":"10.1007\/s10730-013-9219-z"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Baker P, Prue G, Rae J, et al. Jabs for the boys. Int J Mens Soc Community Health. 2019;2(1):e22\u2013e32. https:\/\/doi.org\/10.22374\/ijmsch.v2i1.18","DOI":"10.22374\/ijmsch.v2i1.18"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Law VG, Gustafson DL. Challenging \u2018girls only\u2019 publicly funded human papillomavirus vaccination programmes. Nurs Inq. 2017;24(1):e12140. https:\/\/doi.org\/10.1111\/nin.12140","DOI":"10.1111\/nin.12140"},{"key":"ref14","unstructured":"Brisson M, Jit M, Boily M, et al. Modelling estimates of the incremental effectiveness & cost-effectiveness of HPV vaccination [homepage on the Internet]. Geneva: World Health Organization; 2016 [cited 2023 Nov 12]. Available from: https:\/\/terrance.who.int\/mediacentre\/data\/sage\/SAGE_Docs_Ppt_Oct2016\/10_session_HPV\/Oct2016_session10_HPV_CEA-ICER.pdf"},{"key":"ref15","unstructured":"Tomlinson C. SA adopts single dose HPV vaccine regimen, extends govt-subsidised jabs to private schools [homepage on the Internet]. News24; 2024 [cited 2025 Jul 10]. Available from: https:\/\/www.news24.com\/news24\/southafrica\/news\/sa-adopts-single-dose-hpv-vaccine-regimen-extends-govt-subsidised-jabs-to-private-schools-20240619"}],"container-title":["African Journal of Primary Health Care &amp; Family Medicine"],"original-title":[],"link":[{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/5035\/8689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:44:09Z","timestamp":1759153449000},"score":1,"resource":{"primary":{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/5035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/phcfm.v17i1.5035","relation":{},"ISSN":["2071-2928","2071-2936"],"issn-type":[{"value":"2071-2928","type":"print"},{"value":"2071-2936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"a5035"}}